Document is current
Any future updates will be listed below
-
Authors
Kolb, Hadar
Shachaf, Yuval
Fainberg, Karin
Golan, Maya
Regev, Keren
Vigiser, Ifat
Fuchs, Lior
Gadoth, Avi
Kestenbaum, Meir
Omer, Nurit
Shopin, Ludmila
Ash, Elissa L.
Artzi, Moran
Ben Bashat, Dafna
Aizenstein, Orna
Karni, Arnon https://orcid.org/0000-0002-5625-7900
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02644044 at ClinicalTrials.govDocuments that mention this clinical trial
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up
https://doi.org/10.1007/s00415-025-13114-z
- License Information
-
More Information
Article History
Received: 15 February 2025
Revised: 17 April 2025
Accepted: 22 April 2025
First Online: 4 May 2025
Declarations
:
: All the authors have no conflict of interests to declare that are relevant to the content of this article.
: This study was conducted in accordance with the principles of the Declaration of Helsinki. The Institutional Review Board (IRB) at Tel Aviv Sourasky Medical Center approved the study protocols (IRB No. 166–15).
: Informed consent was obtained from all participants in the Phase 1 study before initiating ITMTX treatment. The IRB waived the need for informed consent in the retrospective study due to the anonymized nature of the data.
